DEPARTMENT OF HEALTH AND HUMAN SERVICES

NATIONAL INSTITUTES OF HEALTH

National Institute on Deafness and Other Communication Disorders (NIDCD)

FY 2021 Budget	<u>Page No.</u>
Organization Chart	2
Appropriation Language	
Amounts Available for Obligation	4
Budget Mechanism Table	5
Major Changes in Budget Request	6
Summary of Changes	7
Budget Graphs	8
Budget Authority by Activity	9
Authorizing Legislation	10
Appropriations History	11
Justification of Budget Request	12
Budget Authority by Object Class	23
Salaries and Expenses	24
Detail of Full-Time Equivalent Employment (FTE)	25
Detail of Positions	26



National Institute on Deafness and Other Communication Disorders

NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS

For carrying out section 301 and title IV of the PHS Act with respect to deafness and other communication disorders, [\$490,692,000]\$446,397,000.

Source of Funding	EV 2010 Einal	EV 2020 Exacted	FY 2021 President's
Source of Funding	FY 2019 Fillal	F I 2020 Enacteu	Budget
Appropriation	\$474,404	\$490,692	\$446,397
Mandatory Appropriation: (non-add)			
Type 1 Diabetes	(0)	(0)	(0)
Other Mandatory financing	(0)	(0)	(0)
Rescission	0	0	0
Sequestration	0	0	0
Secretary's Transfer	-1,630	0	0
Subtotal, adjusted appropriation	\$472,774	\$490,692	\$446,397
OAR HIV/AIDS Transfers	222	0	0
HEAL Transfer from NINDS	0	0	0
Subtotal, adjusted budget authority	\$472,996	\$490,692	\$446,397
Unobligated balance, start of year	0	0	0
Unobligated balance, end of year	0	0	0
Subtotal, adjusted budget authority	\$472,996	\$490,692	\$446,397
Unobligated balance lapsing	-8	0	0
Total obligations	\$472,988	\$490,692	\$446,397

Amounts Available for Obligation¹

(Dollars in Thousands)

¹ Excludes the following amounts (in thousands) for reimbursable activities carried out by this account: FY 2019 - \$1,630 FY 2020 - \$1,000 FY 2021 - \$1,000

Budget Mechanism - Total¹

(Dollars in Thousands)

MECHANISM	FY	2019 Final	FY 2)20 Enacted	FY 2021 P	resident's Budget	1	FY 2021 +/-
						g	FY 2	20 Enacted
	No.	Amount	No.	Amount	No.	Amount	No.	Amount
Research Projects:								
Noncompeting	614	\$249,191	622	\$268,800	589	\$248,640	-33	-\$20,160
Administrative Supplements	(23)	1,498	(28)	2,000	(14)	1,000	(-14)	-1,000
Competing:								
Renewal	34	17,382	36	18,546	33	17,029	-3	-1,517
New	161	64,711	142	55,637	134	51,264	-8	-4,373
Supplements	0	0	0	0	0	0	0	0
Subtotal, Competing	195	\$82,093	178	\$74,183	167	\$68,293	-11	-\$5,890
Subtotal, RPGs	809	\$332,782	800	\$344,983	756	\$317,933	-44	-\$27,050
SBIR/STTR	38	14,639	39	15,143	34	13,645	-5	-1,498
Research Project Grants	847	\$347,422	839	\$360,126	790	\$331,578	-49	-\$28,548
Base and Castern								
Research Centers:	6	\$14.352	7	\$17.016	5	\$11.387	2	\$5.620
Clinical Research	0	\$14,552	,	317,010	0	\$11,587	-2	-\$5,629
Biotechnology	0	0	0	0	0	0	0	0
Comparative Medicine	0	0	0	0	0	0	0	0
Research Centers in Minority Institutions	0	0	0	0	0	0	0	0
Research Centers	6	\$14.352	7	\$17.016	5	\$11.387	0	\$5.629
		\$14,55Z	,	\$17,010		\$11,567	-2	-\$5,629
Other Research:								
Research Careers	46	\$7,698	45	\$7,660	41	\$7,100	-4	-\$560
Cancer Education	0	0	0	0	0	0	0	0
Cooperative Clinical Research	0	0	0	0	0	0	0	0
Biomedical Research Support	0	0	0	0	0	0	0	0
Minority Biomedical Research Support	0	0	0	0	0	0	0	0
Other	28	3,050	28	3,075	25	2,600	-3	-475
Other Research	74	\$10,748	73	\$10,735	66	\$9,700	-7	-\$1,035
Total Research Grants	927	\$372,521	919	\$387,877	861	\$352,665	-58	-\$35,212
Ruth L Kirchstein Training Awards:	FTTPs		FTTPs		<u>FTTPs</u>		<u>FTTPs</u>	
Individual Awards	123	\$5,860	140	\$6,975	130	\$6,400	-10	-\$575
Institutional Awards	157	8,111	155	8,040	154	8,000	-1	-40
Total Research Training	280	\$13,971	295	\$15,015	284	\$14,400	-11	-\$615
Pesearch & Develop Contracts	41	\$20,686	41	\$21,800	37	\$18.430	4	\$3 370
(SPIP/STTP) (non add)	41	(157)	41	\$21,800	37	(281)	-4	-\$3,370
(SBINSTIN) (non-uuu)	(0)	(157)	(0)	(514)	(0)	(201)	(0)	(-55)
Intramural Research	59	42,558	65	42,500	65	38,577	0	-3,923
Res. Management & Support	70	23,259	75	23,500	75	22,325	0	-1,175
Res. Management & Support (SBIR Admin) (non-add)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
Construction		0		0		0		0
Buildings and Facilities		0		0		0		0
Total, NIDCD	129	\$472,996	140	\$490,692	140	\$446,397	0	-\$44,295

¹ All items in italics and brackets are non-add entries.

Major Changes in the Fiscal Year 2021 President's Budget Request

Major changes by budget mechanism and/or budget activity detail are briefly described below. Note that there may be overlap between budget mechanism and activity detail and these highlights will not sum to the total change for the FY 2021 President's Budget for NIDCD, which is \$44.3 million below FY 2020, for a total of \$446.4 million.

Research Project Grants (RPGs) (-\$28.5 million; total \$331.6 million):

NIDCD will fund 790 RPG awards in FY 2021, a decrease of 49 awards from the FY 2020 Enacted level. This includes 589 non-competing awards (a decrease of 33 awards and \$20.2 million from the FY 2020 Enacted level); 167 competing RPGs (a decrease of 11 awards and \$5.9 million from the FY 2020 Enacted level); and 34 SBIR/STTR awards (a decrease of 5 awards and \$1.5 million from the FY 2020 Enacted level).

<u>Research Centers (-\$5.6 million; total \$11.4 million)</u>: NIDCD will fund 5 Center awards in FY 2020, a decrease of 2 from the FY 2020 Enacted level

Other Research (-\$1.0 million; total of \$9.7 million): NIDCD will fund 66 Other Research awards in FY 2021, a decrease of 7 from the FY 2020 Enacted level.

<u>Research Training Awards (-\$0.6 million; total \$14.4 million)</u>: NIDCD will fund 284 Full-Time Training Positions (FTTPs) in FY 2021, a decrease of 11 from the FY 2020 Enacted level.

Summary of Changes

(Dollars in Thousands)

FY 2020 Enacted		\$490,692
FY 2021 President's Budget		\$446,397
Net change		-\$44,295
	FY 2021 President's Budget	Change from FY 2020 Enacted
CHANGES	FTEs Budget Authority	FTEs Budget Authority
A. Built-in:		
1. Intramural Research:		
a. Annualization of January 2020 pay increase & benefits	\$12,424	\$80
b. January FY 2021 pay increase & benefits	12,424	189
c. Paid days adjustment	12,424	-46
d. Differences attributable to change in FTE	12,424	0
e. Payment for centrally furnished services	6,718	-354
f. Cost of laboratory supplies, materials, other expenses, and non-recurring costs	19,435	39
Subtotal		-\$93
2. Research Management and Support:		
a. Annualization of January 2020 pay increase & benefits	\$13,105	\$83
b. January FY 2021 pay increase & benefits	13,105	202
c. Paid days adjustment	13,105	-49
d. Differences attributable to change in FTE	13,105	0
e. Payment for centrally furnished services	2,561	-135
f. Cost of laboratory supplies, materials, other expenses, and non-recurring costs	6,659	-149
Subtotal		-\$48
Subtotal, Built-in		-\$140

	FY 2021 President's Budget		Change from FY 2020 Enacted	
CHANGES	No.	Amount	No.	Amount
B. Program:				
1. Research Project Grants:				
a. Noncompeting	589	\$249,640	-33	-\$21,160
b. Competing	167	68,293	-11	-5,890
c. SBIR/STTR	34	13,645	-5	-1,498
Subtotal, RPGs	790	\$331,578	-49	-\$28,548
2. Research Centers	5	\$11,387	-2	-\$5,629
3. Other Research	66	9,700	-7	-1,035
4. Research Training	284	14,400	-11	-615
5. Research and development contracts	37	18,430	-4	-3,370
Subtotal, Extramural		\$385,495		-\$39,197
	FTEs		FTEs	
6. Intramural Research	65	\$38,577	0	-\$3,830
7. Research Management and Support	75	22,325	0	-1,127
8. Construction		0		0
9. Buildings and Facilities		0		0
Subtotal, Program	140	\$446,397	0	-\$44,155
Total changes				-\$44,295

Fiscal Year 2021 Budget Graphs



History of Budget Authority and FTEs:

Distribution by Mechanism:







Budget Authority by Activity¹ (Dollars in Thousands)

	F	Y 2019 Final	FY	2020 Enacted	FY 2	2021 President's Budget		FY 2021 +/- FY2020
Extramural Research	<u>FTE</u>	<u>Amount</u>	<u>FTE</u>	<u>Amount</u>	FTE	<u>Amount</u>	<u>FTE</u>	<u>Amount</u>
Detail								
Hearing and Balance		\$223,670		\$233,291		\$211,759		-\$21,532
Taste and Smell		62,557		65,247		59,225		-6,022
Voice, Speech, and Language		120,952		126,154		114,511		-11,643
Subtotal, Extramural		\$407,179		\$424,692		\$385,495		-\$39,197
Intramural Research	59	\$42,558	65	\$42,500	65	\$38,577	0	-\$3,923
Research Management & Support	70	\$23,259	75	\$23,500	75	\$22,325	0	-\$1,175
TOTAL	129	\$472,996	140	\$490,692	140	\$446,397	0	-\$44,295

¹ Includes FTEs whose payroll obligations are supported by the NIH Common Fund.

NATIONAL INSTITUTES OF HEALTH	National Institute on Deafness and Other Communication Disorders	

ion
at
60 80
Fe
誝
Z
10
Ħ

	PHS Act/	U.S. Code	2020 Amount	FY 2020 Enacted	2021 Amount	FY 2021 President's Budget
	Other Citation	Citation	Authorized		Authorized	
Research and Investigation	Section 301	42§241	Indefinite		Indefinite	
National Institute on Deafness and Other				\$490,692,000	_^	\$446,397,000
Communication Disorders	Section 401(a)	42§281	Indefinite		Indefinite	
Total. Budget Authority				\$490.692.000		\$446.397.000

Fiscal Year	Budget Estimate to Congress	House Allowance	Senate Allowance	Appropriation
2012	\$426,043,000	\$426,043,000	\$410,482,000	\$417,061,000
Rescission				\$788,245
2013	\$417,297,000		\$418,562,000	\$416,272,755
Rescission				\$832,546
Sequestration				(\$20,894,030)
2014	\$422,936,000		\$420,125,000	\$404,049,000
Rescission				\$0
2015	\$403,933,000			\$405,302,000
Rescission				\$0
2016	\$416,241,000	\$412,366,000	\$424,860,000	\$423,031,000
Rescission				\$0
2017 ¹	\$422,936,000	\$434,126,000	\$441,778,000	\$436,875,000
Rescission				\$0
2018	\$325,846,000	\$443,624,000	\$451,768,000	\$459,974,000
Rescission				\$0
2019	\$423,992,000	\$465,467,000	\$474,653,000	\$474,404,000
Rescission				\$0
2020	\$408,358,000	\$497,590,000	\$500,270,000	\$490,692,000
Rescission				\$0
2021	\$446,397,000			

Appropriations History

¹ Budget Estimate to Congress includes mandatory financing.

Justification of Budget Request

National Institute on Deafness and Other Communication Disorders

Authorizing Legislation: Section 301 and title IV of the Public Health Service Act, as amended.

			FY 2021	
	FY 2019	FY 2020	President's	FY 2021+/-
	Final	Enacted	Budget	FY 2020
BA	\$472,996,000	\$490,692,000	\$446,397,000	-\$44,295,000
FTE	129	140	140	0

Program funds are allocated as follows: Competitive Grants/Cooperative Agreements; Contracts; Direct Federal/Intramural and Other.

Director's Overview

At least 46 million people in the United States have a hearing or other communication disorder.¹ For these individuals, the basic components of communication – sensing, interpreting, and responding to people and things in our environment – can be challenging. The National Institute on Deafness and Other Communication Disorders (NIDCD) manages a broad portfolio of basic, translational, clinical, and public health research focused on human communication and associated disorders in three program areas: hearing and balance; taste and smell; and voice, speech, and language.

Highlights of NIDCD Research Advances from Mission Areas:

Extraordinary research opportunities have led to scientific breakthroughs in the study of genes, proteins, cellular and molecular processes, neural circuits, and sensory and motor systems that directly affect our understanding of communication disorders. For example, NIDCD-supported research has led to advances in the following areas of communication science:

New Discoveries Could Help Treat Hereditary Hearing Loss:² NIDCD has long been interested in the identification of genetic mutations associated with hereditary hearing loss. For example, in 1995, NIDCD scientists identified the first genetic mutation associated with Usher syndrome, a rare disorder that affects hearing, balance, and vision. Individuals with Usher syndrome have profound loss of hearing and balance because the sensory hair cells in the inner ear develop and function abnormally. By 2013, at least 10 additional Usher syndrome mutation into zebrafish and successfully identified the process by which the genetic mutation disrupted sensory hair cell function. Further, the scientists discovered that a common antimalarial drug, artemisinin, could counteract this disruption and preserve sensory hair cell function in treated zebrafish. NIDCD plans to translate this finding in zebrafish to mammals and eventually to

¹ www.nidcd.nih.gov/about/strategic-plan/2017-2021/introduction

² www.ncbi.nlm.nih.gov/pubmed/31097578

humans with Usher Syndrome. NIDCD will continue to strive to discover new genetic mutations that may cause rare types of hearing loss and balance disorders and to use this information to develop new therapies to treat affected individuals.

Identification of an Elusive Sour Taste Receptor:^{3,4} Taste plays a critical role in helping us determine what is safe to eat and what might be poisonous. Although we know how most tastes are detected, scientists have been searching for the elusive receptor that detects sour taste. In 2018, NIDCD-supported scientists identified a likely candidate when they discovered how a protein called OTOP1 forms channels that allow protons to enter sour taste receptor cells on the tongue. Recently, NIDCD-supported scientists described the three-dimensional structure and electrostatic charge interactions of residues within channel proteins OTOP1 and 3 to determine how they control cellular proton entry. Now, the same scientists collaborated on another NIDCD-supported study to test sour taste sensitivity in mice that lack the gene (Otop1) needed to make the OTOP1 channel protein. The sour taste cells in mice lacking OTOP1 had reduced responses to sour-tasting liquids, providing evidence that OTOP proteins play a critical role in detecting sour tastes on the tongue. Understanding how we perceive sour taste will provide insight into why we seek out particular foods and avoid others. NIDCD will continue to support research focused on understanding the basic mechanisms of taste and smell to help understand how taste and smell contribute to flavor perception and food selection.

Scientists Discover Brain Cells Involved in Stuttering:⁵ Stuttering occurs primarily in young children, most of whom eventually outgrow the problem. However, for one quarter of children with early onset stuttering, the condition persists as a life-long communication problem. For several decades, scientists have been unable to identify the causes of persistent stuttering. A breakthrough occurred 10 years ago when NIDCD scientists identified the first genetic mutations in humans associated with stuttering. Now, in a recent advance, NIDCD researchers identified changes in the brain brought on by one of the gene mutations previously linked to stuttering. The scientists made this discovery by engineering one of the human stuttering gene mutations into mice and then studying the mouse vocalizations. They found that mice with the mutation had long pauses in their streams of vocalizations, somewhat similar to those found in the speech of people with the same mutation. The scientists also noticed these mice had a loss of astrocytes - a type of brain supporting cell - in the corpus callosum, which is a part of the brain that enables communication between the brain's left and right hemispheres. The corpus callosum helps integrate signals for processes that involve both hemispheres, such as physical coordination and use of language. The identification of genetic, molecular, and cellular changes that underlie stuttering has led scientists to understand persistent stuttering as a brain disorder. Future research will focus on understanding what brain regions and specific cells are involved, in order to open opportunities for novel interventions for stuttering – and possibly other speech disorders.

NIDCD Plans, Priorities, and Challenges for the Future: Over the past 30 years, researchers supported by the NIDCD have made seminal advances in understanding the normal and disordered processes of hearing, balance, taste, smell, voice, speech, and language, leading to increasingly effective, evidence-based treatments for conditions that affect an ever growing

³ www.ncbi.nlm.nih.gov/pubmed/31160780

⁴ www.ncbi.nlm.nih.gov/pubmed/31543453

⁵ www.ncbi.nlm.nih.gov/pubmed/31405983

segment of the U.S. population. Moving forward, NIDCD staff, with the guidance of the Institute's advisory committees – the National Deafness and Other Communication Disorders Advisory Council and the Board of Scientific Counselors – will examine NIDCD's current portfolio and priorities, opportunities for partnerships, and the needs of the Institute's targeted populations and constituencies to develop a strategic plan with a vision toward the future. NIDCD expects current efforts to culminate in a new research strategic plan in calendar year 2022. The Institute's vision is that all Americans benefit from scientific discovery that informs effective and accessible treatments and improves quality of life.

NIDCD continues its support of new and competing Research Project Grants from investigators who have innovative ideas. NIDCD prioritizes its research investments to identify the most promising opportunities for research on deafness and other communication disorders and is committed to identifying effective interventions for the treatment or prevention of communication disorders by supporting well-designed and well-executed clinical trials. NIDCD funding announcements reflect investments in clinical trials that advance the care of individuals with deafness and other communication disorders.^{6,7} Further, NIDCD supports an announcement on "Translating Basic Research into Clinical Tools"⁸ which provides an avenue for basic research scientists, clinicians, and clinical scientists to translate basic research into practical applications.

NIDCD prioritizes and supports Early-Stage Investigators (ESIs), defined as investigators who are within 10 years of receiving their terminal educational degree. The Institute has a long history of supporting ESIs, through early stages of career development with special programs including the Early Career Research Award (implemented in 1990) and the expedited review of pre- and post-doctoral Fellowship applications (implemented in 2000). In 2019, five NIDCD ESIs were honored with the Presidential Early Career Award for Scientists and Engineers, the highest honor bestowed by the Federal Government on outstanding scientists beginning their independent career. NIDCD's longstanding support of diverse, interdisciplinary ESIs ensures a robust pipeline of scientists pursuing research to tackle the world's complex public health needs.

Overall Budget Policy:

The FY 2021 President's Budget request for NIDCD is \$446.4 million, a decrease of \$44.3 million or 9.0 percent compared with the FY 2020 Enacted level.

Program Descriptions and Accomplishments

Hearing and Balance Program: Loss of hearing or balance imposes a significant social and economic burden upon individuals, their families, and the communities in which they live. Hearing and balance disorders cross all ethnic and socioeconomic lines. Among adults, hearing loss is the third most common chronic condition in the United States.⁹ The prevalence of hearing loss increases with age, with nearly 25 percent of adults aged 65-74 having a disabling hearing

⁶ www.grants.nih.gov/grants/guide/pa-files/PA-18-334.html

⁷ www.grants.nih.gov/grants/guide/pa-files/PAR-18-340.html

⁸ www.grants.nih.gov/grants/guide/pa-files/PAR-18-533.html

⁹ www.cdc.gov/nchs/data/series/sr_10/sr10_260.pdf

loss.¹⁰ This rate increases to 50 percent for those who are 75 and older.¹⁰ This fact, along with the aging demographic in the United States will account for an increasing burden of age-related hearing loss in the years ahead. About 2 out of every 1,000 children in the United States are born with a detectable level of hearing loss in one or both ears that can affect their speech, language, social, and cognitive development.¹¹ More than 1 in 20 American children have a dizziness or balance problem.¹² Accordingly, NIDCD supports research that will lead to improved treatments for, and prevention of, hearing and balance disorders. These research projects encompass over half of NIDCD's grant portfolio.

Ear infections are one of the most common reasons parents bring their child to a doctor. In some of these cases, the ear infection can persist or recur. NIDCD-supported scientists are leading research to discover how a common bacterium, *Haemophilus influenzae*, causes recurrent ear infections.¹³ By creating biofilms, a thin film of bacteria that adheres on the surface of the middle ear, the bacteria create a protective blanket that shields them from immune system responses and antibiotic treatments. Using a mouse model, researchers discovered a bacterial scaffolding that is important for creating and maintaining biofilms, thus explaining why some infections may linger or reoccur. By targeting this structure, the researchers prevented biofilms from forming and broke apart existing biofilms, making it easier to permanently kill the bacteria with antibiotics.¹⁴ In future work, scientists will study whether treatments that break down biofilms could help prevent persistent ear infections.

Roughly 10 percent of American adults have experienced tinnitus, often described as a ringing in the ears.¹⁵ For many, tinnitus can be severe and unremitting, and – especially in these cases – can be associated with decreased quality of life. While there is no cure, some interventions can reduce the severity. NIDCD supports research to determine the neural basis of tinnitus and to identify behavioral, pharmacological, surgical, and device-based treatments for improving tinnitus symptoms.¹⁶ For example, NIDCD-supported scientists conducted the first clinical trial comparing the standard of care (patient-centered counseling) to Tinnitus Retraining Therapy (patient-centered counseling and the use of a sound generator to help tune out tinnitus).¹⁷ The researchers found no added benefit of the sound generator device, which can be very costly. In another example, researchers are exploring brain stimulation to treat difficult tinnitus cases. Hyperactivity in a region of the brainstem that integrates sound and touch information may underlie tinnitus in some individuals.¹⁸ Using this information, researchers piloted a novel and non-invasive treatment for tinnitus by stimulating this brain area in rodents and humans.¹⁹ Another group of NIDCD-funded researchers performed a clinical trial of deep brain stimulation

¹⁰ www.nidcd.nih.gov/health/statistics/quick-statistics-hearing

¹¹ www.cdc.gov/mmwr/preview/mmwrhtml/mm5908a2.htm

¹² www.nidcd.nih.gov/news/2016/more-1-20-us-children-have-dizziness-and-balance-problems

¹³ www.ncbi.nlm.nih.gov/pubmed/30853830

¹⁴ www.ncbi.nlm.nih.gov/pubmed/31021431

¹⁵ www.nidcd.nih.gov/health/statistics/quick-statistics-hearing#7

¹⁶ www.nidcd.nih.gov/about/strategic-plan/2017-2021/priority-areas-hearing-and-balance-research

¹⁷ www.ncbi.nlm.nih.gov/pubmed/31120533

¹⁸ www.ncbi.nlm.nih.gov/pubmed/30217755

¹⁹ www.ncbi.nlm.nih.gov/pubmed/29298868

in a different brain area – an area which links sound information with emotional state.²⁰ These treatments show promise for those who experience tinnitus. Future clinical trials could allow for the commercialization of these techniques.

A balance disorder is a disabling condition, is common among the elderly, and is one of the primary causes of falls. In 2015, the total medical costs for falls totaled more than \$50 billion.²¹ Medicare and Medicaid bore 75 percent of these costs.²¹ To understand better how aging affects the vestibular system, NIDCD and the National Institute on Aging (NIA) convened a scientific workshop in 2019 on the Central and Peripheral Control of Balance in Older Adults. The workshop focused on the following topics: balance and the aging brain; diagnosis and assessment of balance disorders; leveraging new technologies in the assessment and management of balance disorders; and balance interventions, therapies, and targets for treatments. Representatives with expertise in basic, clinical, epidemiologic and population health research in the fields of gerontology, geriatrics, vestibular physiology, neurology, neuroscience, movement science, movement disorders, and rehabilitation participated in the workshop. The discussions provided NIDCD and NIA with a research blueprint to increase our understanding of the aging of the vestibular system and facilitate effective management of mobility disability, falls, and cognitive impairment in older adults.

There are currently no effective treatments for some balance disorders, which may be caused by damaged vestibular hair cells in the inner ear. In a landmark study, NIDCD-supported scientists were the first to restore the sense of balance in mice by manipulating a protein that regulates the hair cells in the inner ear that are responsible for balance.²² This discovery may be an important first step towards treating vestibular disorders, or dizziness. In the study, the scientists damaged vestibular hair cells in mice and discovered that approximately one third of the hair cells regenerated spontaneously but appeared immature and the mice did not recover their balance. The scientists then engineered a protein, Atoh1, which regulates inner ear hair cell formation, to be expressed in abundance. In the mice that overexpressed Atoh1, as much as 70 percent of vestibular hair cells regenerated and about 70 percent of these mice recovered their balance. This finding opens the door to new research that may lead to treatment for the 35 million American adults who report having a balance or dizziness problem.

PROGRAM PORTRAIT: Ending the 40-Year Quest to Find the Hearing and Balance Key Sensory Protein

NIDCD-supported scientists have identified the key sensory protein for hearing and balance, TMC1, which is responsible for converting sound and movement into electrical signals that the brain can interpret. The key proteins for most other senses have been identified, but this pivotal hearing protein has been elusive for more than 40 years.

The TMC1 protein, abbreviated from "transmembrane cochlear-expressed gene 1," forms an ion channel located in the membrane of sensory hair cells in the inner ear. These hair cells are found in the cochlea (the organ responsible for hearing) and in the semi-circular canals (the structures responsible for balance and motion detection). Sound vibrations and head movements cause stereocilia (bristly projections that perch atop the hair cells) to bend, thus causing the TMC1 channel to open letting positively charged ions into the cell. This process, called mechanotransduction, converts a mechanical signal into an electrical signal that the brain can interpret as sound or

²⁰ www.ncbi.nlm.nih.gov/pubmed/31553940

²¹ www.cdc.gov/homeandrecreationalsafety/falls/adultfalls.html

²² www.ncbi.nlm.nih.gov/pubmed/31291569

movement. Mechanotransduction from the inner ear to the brain was first discovered in the 1970s, but no one knew which genes and their corresponding proteins were responsible.

Researchers identified TMC1 in 2002 by conducting gene mapping studies of a large North American family with deafness and 11 unrelated families from Pakistan and India with the same kind of hereditary deafness.²³ The researchers found that in all 12 families, 1 of 8 different mutations in the TMC1 gene was responsible for the hearing loss. Animal models with mutations in the mouse version of TMC1 were also profoundly deaf, and tests showed that the cochlear hair cells showed no electrical response to sound stimulation. While the newly discovered gene was important for normal hearing, scientists were not able to determine if it was the gatekeeper for mechanotransduction.

Almost 10 years later, NIDCD-supported scientists discovered another piece of the puzzle.²⁴ Using genetically engineered mice where the TMC1 gene was deleted, the researchers found a specific functional deficit in the mechanotransduction channels of the mice's stereocilia, but the rest of the hair cell's structure and function was normal. When the researchers used gene therapy to re-introduce a functional copy of TMC1 to hair cells, they saw that mechanotransduction was restored.

In 2013, NIDCD-supported scientists found that changing one base or "letter" in the genetic sequence of TMC1 was enough to change, but not destroy, the properties and function of the ion channels that resulted in progressive deafness.²⁵ A later study used powerful microscopy techniques to pinpoint the precise cellular location of the TMC1 protein in the inner ear of mice.²⁶ They found that TMC1 was localized predominately in the stereocilia tips, the site of mechanotransduction, providing further evidence that TMC1 was likely part of the elusive hair cell mechanotransduction channel.

In 2018, a team of NIDCD-supported scientists studied the precise structure and function of the amino acids that made up the TMC1 protein.²⁷ They identified the region of the protein that was hypothesized to make up the channel (or pore). They substituted the 17 amino acids of the pore region one at a time to gauge whether and how each substitution altered the hair cells' ability to respond to sound and affected the flow of ions. Of the 17 substitutions, 11 altered the influx of ions, and 5 did so dramatically, reducing flow by up to 80 percent. One substitution blocked ion influx, a finding that confirmed the precise location of the pore that initiates mechanotransduction. This finding helped definitively confirm that TMC1 was a component of the mechanotransduction channel for hearing and balance.

Knowing the precise structure and function of TMC1 enables scientists to gain new insights into disorders of hearing and balance. This discovery also lays the groundwork for precision-targeted therapies to treat hearing loss when the TMC1 gene is mutated or missing. NIDCD will continue to fund basic research to define the spectrum of genetic contributions to inherited hearing loss and to understand the structural and functional consequences of such mutations with the goal to develop new therapies to prevent hearing loss or restore hearing and balance function.

Budget Policy:

The FY 2021 President's Budget request for the Hearing and Balance program is \$211.8 million, a decrease of \$21.5 million or 9.2 percent compared with the FY 2020 Enacted level. In FY 2021, the program will continue emphasizing faculty, postdoctoral, and student training on hearing and balance sciences. Postdoctoral fellows who show high promise as emerging independent investigators will be encouraged to launch their careers through the Pathways to Independence (K99-R00) program. Making R01 awards to first-time and early-stage investigators in the area of hearing and balance sciences will be given funding priority.

²³ www.ncbi.nlm.nih.gov/pubmed/11850618

²⁴ www.ncbi.nlm.nih.gov/pubmed/22105175

²⁵ www.ncbi.nlm.nih.gov/pubmed/23871232

²⁶ www.ncbi.nlm.nih.gov/pubmed/26321635

²⁷ www.ncbi.nlm.nih.gov/pubmed/30138589

Taste and Smell Program: Taste and smell disorders are underreported, and often undiagnosed. NIDCD supports studies of the chemical senses known as taste, smell, and chemesthesis (chemically provoked irritation) to enhance our understanding of how individuals gather information about their environment and how human chemosensory disorders can be diagnosed and treated. With age, the olfactory (sense of smell) system is less able to repair and regenerate, and our sense of smell declines. Although prevalence estimates vary, it is likely that more than one third of adults over the age of 70 have olfactory deficits.²⁸ Since both taste and smell contribute to flavor perception, such olfactory deficits affect the flavor of foods and consequently negatively affect food intake, diet, overall nutrition, and health status. NIDCD encourages further studies of age-related decline in olfactory sensitivity including the development of better diagnostic tests to assess chemosensory loss and animal models to study why this decline occurs and how to prevent or treat it.

NIDCD supports basic research to understand how mosquitos "smell" humans in order to control and prevent insect-borne diseases. The mosquito *Aedes aegypti*, which transmits dengue, Zika, yellow fever, and chikungunya, is adapted to life in populated areas. Female *Ae. aegypti* mosquitos preferentially seek out humans for blood meals to develop their eggs. Scientists are hoping to learn how to prevent mosquitos from biting and spreading disease by understanding the signaling molecules that drive mosquito feeding behavior. After a blood meal, female mosquitos temporarily lose interest in seeking more blood. NIDCD-supported scientists have combined powerful molecular tools with studies of mosquito behavior to identify a receptor – Neuropeptide Y-like receptor 7 (NPYLR7) – that, when activated, prevents mosquitos from seeking human blood meals.²⁹ Scientists hope to develop ways to deliver molecules that activate NPYLR7 to mosquitos to prevent human blood-seeking and prevent subsequent mosquito-borne illnesses.

Our sense of taste plays a broader role than determining what we eat – in some cases, it can also determine whether we take lifesaving medicines. The bitter taste of HIV treatment drugs such as KaletraTM, for example, causes some children to refuse to take this important medication. Taste scientists know that people demonstrate a range of variations in preference and avoidance of different tastes. Although scientists suspect that variations in genes underly individual taste preference, we still don't know which genes underly which preferences. NIDCD-supported scientists tested "palatability," or taste acceptability, of the HIV medicine KaletraTM on a panel of adult tasters, and looked at gene expression – or genotype – in the individuals who accepted the taste as compared to those who could not tolerate it.³⁰ They discovered that a panelist's palatability of KaletraTM varied along with expression of two particular taste-related genes, and that panelists gave the same palatability ratings on subsequent tests. The next step will be to determine whether the same patterns of taste preference variation observed in adults are also true for children. Scientists may then be ready to develop tools to predict which children will reject the taste of certain drugs.

²⁸ NIDCD Epidemiology and Statistics Branch calculation

²⁹ www.ncbi.nlm.nih.gov/pubmed/30735632

³⁰ www.ncbi.nlm.nih.gov/pubmed/28923290

Budget Policy:

The FY 2021 President's Budget request for the Taste and Smell program is \$59.2 million, a decrease of \$6.0 million or 9.2 percent compared with the FY 2020 Enacted level. In FY 2020, the program will continue emphasizing faculty, postdoctoral, and student training on smell and taste sciences. Postdoctoral fellows who show high promise as emerging independent investigators will be encouraged to launch their careers through the Pathways to Independence (K99-R00) program. Making R01 awards to first-time and early-stage investigators in the area of smell and taste sciences will be given funding priority.

Voice, Speech, and Language Program: Disorders involving voice, speech, or language can have an overwhelming effect on an individual's health and quality of life. These disorders affect people of all ages with or without hearing impairment, such as children with autism, people who stutter, and adults with acquired communication disorders. Voice, speech, and language disorders also come at a significant cost. The societal burden of laryngeal disorders is estimated at \$11 billion annually due to work-related disability, lost productivity, and direct health care cost.³¹ Further, nearly eight percent of children ages 3-17 years have had a communication disorder during the past 12 months, according to data from the National Health Interview Survey, 2012.³² By the first grade, roughly five percent of children have noticeable speech disorders.³³ In children, delayed speech and language acquisition or impairment are very often significant predictors of future academic, social, vocational, and adaptive outcomes.³⁴

Autism spectrum disorders (ASD) are a group of developmental disabilities that can cause significant social, communication, and behavioral challenges. According to the Centers for Disease Control and Prevention, about 1 in 59 children is diagnosed with ASD. NIDCD has identified a number of research needs and opportunities related to children with autism, and in particular, among the 25-30 percent of children with ASD who remain functionally non-verbal beyond 5 years of age – a subset under-represented in autism research. Many infants at risk for ASD show differences in the development of social attention and early forms of communication over the first year of life, but reliable assessment measures for these developmental delays are lacking. NIDCD supports research to examine and measure differences in speech and language abilities in ASD individuals. In one study, NIDCD-supported scientists are using functional imaging to discover neural biomarkers for language and social development in ASD toddlers. These researchers found distinct neurobiology and gene expression in ASD subtypes with variable early language outcomes – well before such outcomes were known.³⁵ In another study funded in part by NIDCD, scientists were able to accurately predict ASD in babies as young as three months old based on their brain's electrical activity.³⁶ Further, NIDCD is participating in two funding opportunity announcements to support research for "Early Screening for ASD,"37,38 to improve the early diagnosis of ASD and ultimately to develop effective treatments to address

³¹ www.ncbi.nlm.nih.gov/pubmed/22549455

³² www.cdc.gov/nchs/products/databriefs/db205.htm

³³ www.ahrq.gov/downloads/pub/prevent/pdfser/speechsyn.pdf

³⁴ www.ncbi.nlm.nih.gov/pubmed/18695010: www.ncbi.nlm.nih.gov/pubmed/17883441:

www.ncbi.nlm.nih.gov/pubmed/15679523

³⁵ www.ncbi.nlm.nih.gov/pubmed/30482947

³⁶ www.ncbi.nlm.nih.gov/pubmed/29717196

³⁷ www.grants.nih.gov/grants/guide/rfa-files/rfa-mh-19-120.html

³⁸ www.grants.nih.gov/grants/guide/rfa-files/RFA-MH-19-121.html

the communication challenges faced by many with ASD. As a result, NIDCD co-funded one project with relevance to our mission area.

NIDCD also supports basic, clinical, and translational research on voice disorders for individuals that have impaired function due to injury or disease. Vocal fold paralysis (also known as vocal cord paralysis) is a voice disorder that occurs when one or both of the vocal folds don't open or close properly. Single vocal fold paralysis is a common disorder. Paralysis of both (bilateral) vocal folds (BVFP) is rare and can be life threatening because it causes serious problems with breathing. Treatment involves cutting the vocal fold to improve ventilation, but the surgery damages the voice and compromises swallowing. NIDCD supports a clinical trial to develop an electrical stimulation technology to help people with BVFP avoid surgery and improve vocal fold function.³⁹ The device, which currently is being tested in animals and people, uses an implanted pacemaker to stimulate laryngeal nerves. Researchers hope that bilateral stimulation will return mobility to the vocal folds so that they can open to allow breathing and close to allow speaking and swallowing.

Augmentative and alternative communication (AAC) devices help people with voice, speech, or language disorders communicate. People with amyotrophic lateral sclerosis (or motor neuron disease) or brainstem stroke lose their ability to move their arms, legs, or body. They can also become locked-in, where they are not able to speak, even though they are able to think and reason normally. However, with the advent of brain-computer interface (BCI) technology, which uses sensors to measure electrical signals in the brain to run a computer, NIDCD scientists believe they have found a way to restore hope to these individuals. In an important advance, NIDCD-supported engineers developed an approach to turn a person's thoughts directly into speech.⁴⁰ The scientists trained a computer algorithm – that is typically used to interpret voice commands - to decipher brain activity instead. Individuals with epilepsy undergoing brain surgery listened to sentences spoken by different people. The researchers used the neural patterns measured from these patients to train the computer algorithm. When the patients simply thought of the words they had heard, the algorithm was able to accurately decipher the thoughts 75 percent of the time. NIDCD will continue to invest in assistive communication devices, such as BCI technology, to help people with amyotrophic lateral sclerosis, stroke, or neurodegenerative disease regain their ability to communicate.

Budget Policy:

The FY 2021 President's Budget request for the Voice, Speech, and Language program is \$114.5 million, a decrease of \$11.6 million or 9.2 percent compared with the FY 2020 Enacted level. In FY 2021, the program will continue emphasizing faculty, postdoctoral, and student training on voice, speech, and language sciences. Postdoctoral fellows who show high promise as emerging independent investigators will be encouraged to launch their careers through the Pathways to Independence (K99-R00) program. Making R01 awards to first-time and early-stage investigators in the area of voice, speech, and language sciences will be given funding priority.

³⁹ www.projectreporter.nih.gov/project_info_description.cfm?aid=9744672

⁴⁰ www.ncbi.nlm.nih.gov/pubmed/30696881

Intramural Research Program (IRP): The NIDCD Intramural Research Program conducts basic and clinical research in human communication, with a primary focus on hearing and balance.

Other NIDCD intramural scientists are taking advantage of the Cancer Genome Atlas (TCGA) consortium, a joint effort of the NIH's National Cancer Institute and National Human Genome Research Institute that is a culmination of more than a decade of work by more than 150 researchers across North America. They studied the genomic profiles of a type of head and neck cancer, called squamous cell carcinoma (SSC), to develop targeted treatments. They uncovered molecular characteristics that distinguish the genomic profiles of SCCs apart from other cancers.⁴¹ This research can lead to more effective diagnosis and treatment of these cancers by helping researchers develop tailored strategies for specific cancer subtypes. Here, the researchers went on to explore the impact of a specific micro-RNA that was reduced in these cancers. They found that this small molecule helps regulate signaling networks and suppress tumors⁴². Since the loss of this micro RNA likely reduces people's ability to fight off the cancer, therapies to increase its levels in the body could be a precision-medicine approach to treating these types of cancer.

In another intramural project, scientists are exploring the cellular implications of variations of a gene, TRIO and F-Actin Binding Protein (TRIOBP), which has been known to cause profound deafness in humans and mice.⁴³ Using mice as a model, the researchers learned that this gene is vital to development of key sensory structures in the inner ear called stereocilia. Stereocilia sit atop hair cells in the inner ear and sway with vibrations caused by sound. This motion causes the hair cell to send a signal to the brain which is interpreted as sounds we recognize and understand. The researchers discovered that TRIOBP is involved in supporting the cellular skeleton of the stereocilia. A protein called actin makes the core of this skeleton inside the stereocilia and forms a root to connect it securely to the hair cell. The researchers found that the variations of the TRIOBP gene weaken the actin root, causing the stereocilia to be floppy and unable to respond appropriately to sound vibrations. This research helps explain how we hear, why mutations in TRIOBP cause deafness, and hints at possibilities for future therapies for this gene variation.

Menthol provides a minty taste and a cooling or soothing sensation but long has played a particularly troubling role in U.S. cigarette smoking patterns. Nearly 20 million people in the United States smoke menthol cigarettes, which are particularly popular among African-American and teen smokers.⁴⁴ NIDCD intramural scientists identified a genetic variant found only in a subset of people of African descent that significantly increases a smoker's preference for cigarettes containing menthol.⁴⁵ The gene variant is five to eight times more frequent among smokers who use menthol cigarettes than other smokers. The multiethnic study is the first to look across all genes to identify genetic vulnerability to menthol cigarettes. This finding could inform policies on menthol flavoring in combustible and e-cigarettes.

⁴¹ www.ncbi.nlm.nih.gov/pubmed/29617660

⁴² www.ncbi.nlm.nih.gov/pubmed/30723145

⁴³ www.ncbi.nlm.nih.gov/pubmed/31217345

⁴⁴ www.fda.gov/tobacco-products/products-ingredients-components/menthol-and-other-flavors-tobacco-products

⁴⁵ www.ncbi.nlm.nih.gov/pubmed/30768591

Budget Policy:

The FY 2021 President's Budget request for the Intramural Research program is \$38.6 million, a decrease of \$3.9 million or 9.2 percent compared with the FY 2020 Enacted level. The NIDCD Intramural Research Program has been a leader in research on hereditary hearing impairment and has identified many genes whose mutation causes hearing loss. In FY 2021, NIDCD intramural scientists will continue their efforts in identifying mutation in genes, which impacts hearing, and identifying or studying additional genes involved in communication disorders in humans and animal models.

Research Management and Support (RMS) Program: NIDCD RMS activities provide administrative, budgetary, logistical, and scientific support in the review, award, and monitoring of research grants, training awards, and research and development contracts. RMS functions also include strategic planning, coordination, and evaluation of the Institute's programs, regulatory compliance, international coordination, and liaison with other Federal agencies, Congress, and the public. The Institute currently supports approximately 1,400 research grants, training awards, and research and development (R&D) contracts.

Dr. Debara L. Tucci became the NIDCD Director on September 3, 2019. She is the NIDCD's first woman in this role and the institute's fourth director since it was founded in 1988. Dr. Tucci has been recognized as a pioneer in her work to understand the causes and impact of hearing loss and to develop treatments to restore hearing. Prior to joining NIDCD, she was on the faculty of Duke University Medical Center in Durham, North Carolina, for more than 25 years, where she co-founded the Duke Hearing Center and directed the medical center's cochlear implant program. Dr. Tucci's vision is that all people with disorders of hearing, balance, taste, smell, voice, speech, or language will benefit from scientific discovery that informs effective and accessible treatments and improves quality of life.

Budget Policy:

The FY 2021 President's Budget request for the Research Management and Support program is \$22.3 million, a decrease of \$1.2 million or 5.0 percent compared with the FY 2020 Enacted level.

Budget Authority by Object Class¹

(Dollars in Thousands)

		FY 2020 Enacted	FY 2021 President's Budget	FY 2021 +/- FY 2020
Total co	mpensable workyears:			
	Full-time equivalent	140	140	0
	Full-time equivalent of overtime and holiday hours	0	0	0
	Average ES salary	\$192	\$192	\$0
	Average GM/GS grade	12.4	12.4	0.0
	Average GM/GS salary	\$122	\$123	\$1
	Average salary, grade established by act of July 1,	\$134	\$138	\$A
	1944 (42 U.S.C. 207)	\$134	\$130	φ τ
	Average salary of ungraded positions	\$107	\$108	\$1
			FY 2021 President's	FY 2021
	OBJECT CLASSES	FY 2020 Enacted	Budget	+/-
	Personnel Compensation			F Y 2020
111	Full Time Dermonent	11.084	12 122	129
11.1	Other Than Full Time Dormanant	11,964	12,122	130
11.5	Other Parsonnal Comparisation	4,013	4,070	55
11.5	Military Personnel	130	410	3
11.7	Special Personnel Services Payments	150	134	18
11.0	Subtotal Personnel Companyation	\$18 013	\$10.132	\$210
12.1	Civilian Personnel Benefits	6 096	6 333	219
12.1	Military Personnel Benefits	61	63	238
12.2	Renefits to Former Personnel	0	0	2
15.0	Subtotal Pay Costs	\$25,070	\$25.529	\$459
21.0	Travel & Transportation of Persons	338	141	-197
22.0	Transportation of Things	26	6	-19
23.1	Rental Payments to GSA	0	0	0
23.2	Rental Payments to Others	0	0	0
23.3	Communications, Utilities & Misc. Charges	117	119	2
24.0	Printing & Reproduction	0	0	0
25.1	Consulting Services	135	62	-72
25.2	Other Services	7,618	5,474	-2,144
25.3	Purchase of goods and services from government	46,420	42,291	-4,129
25.4	Operation & Maintenance of Facilities	165	165	0
25.4	R&D Contracts	3 073	2 548	-525
25.5	Medical Care	204	2,340	8
25.0	Operation & Maintenance of Equipment	1 031	1 052	21
25.8	Subsistence & Support of Persons	24	25	0
25.0	Subtotal Other Contractual Services	\$58,670	\$51,828	-\$6,841
26.0	Supplies & Materials	1,890	928	-962
31.0	Equipment	1,690	781	-909
32.0	Land and Structures	0	0	0
33.0	Investments & Loans	0	0	0
41.0	Grants, Subsidies & Contributions	402,892	367,065	-35,827
42.0	Insurance Claims & Indemnities	0	0	0
43.0	Interest & Dividends	0	0	0
44.0	Refunds	0	0	0
	Subtotal Non-Pay Costs	\$465,622	\$420,868	-\$44,754
	Total Budget Authority by Object Class	\$490,692	\$446,397	-\$44,295

¹ Includes FTEs whose payroll obligations are supported by the NIH Common Fund.

Salaries and Expenses

(Dollars in Thousands)

OBJECT CLASSES	FY 2020 Enacted	FY 2021 President's Budget	FY 2021 +/- FY 2020	
Personnel Compensation				
Full-Time Permanent (11.1)	\$11,984	\$12,122	\$138	
Other Than Full-Time Permanent (11.3)	4,815	4,870	55	
Other Personnel Compensation (11.5)	411	416	5	
Military Personnel (11.7)	130	134	3	
Special Personnel Services Payments (11.8)	1,572	1,590	18	
Subtotal Personnel Compensation (11.9)	\$18,913	\$19,132	\$219	
Civilian Personnel Benefits (12.1)	\$6,096	\$6,333	\$238	
Military Personnel Benefits (12.2)	61	63	2	
Benefits to Former Personnel (13.0)	0	0	0	
Subtotal Pay Costs	\$25,070	\$25,529	\$459	
Travel & Transportation of Persons (21.0)	\$338	\$141	-\$197	
Transportation of Things (22.0)	26	6	-19	
Rental Payments to Others (23.2)	0	0	0	
Communications, Utilities & Misc. Charges (23.3)	117	119	2	
Printing & Reproduction (24.0)	0	0	0	
Other Contractual Services:				
Consultant Services (25.1)	135	62	-72	
Other Services (25.2)	7,618	5,474	-2,144	
Purchases from government accounts (25.3)	30,434	28,878	-1,557	
Operation & Maintenance of Facilities (25.4)	165	165	0	
Operation & Maintenance of Equipment (25.7)	1,031	1,052	21	
Subsistence & Support of Persons (25.8)	24	25	0	
Subtotal Other Contractual Services	\$39,407	\$35,656	-\$3,751	
Supplies & Materials (26.0)	\$1,890	\$928	-\$962	
Subtotal Non-Pay Costs	\$41,777	\$36,849	-\$4,928	
Total Administrative Costs	\$66,847	\$62,378	-\$4,469	

	FY 2019 Final		FY 2020 Enacted			FY 2021 President's Budget			
OFFICE/DIVISION	Civilian	Military	Total	Civilian	Military	Total	Civilian	Military	Total
Division of Extramural Activities	10		10	20		20	20		20
Direct:	19	-	19	20	-	20	20	-	20
Reimbursable:	-	-	-	-	-	-	-	-	-
Total:	19	-	19	20	-	20	20	-	20
Division of Intramural Research Program									
Direct:	56	1	57	64	1	65	64	1	65
Reimbursable:	2	-	2	-	-	-	-	-	-
Total:	58	1	59	64	1	65	64	1	65
Division of Scientific Programs									
Direct:	16		16	18	_	18	18	_	18
Reimbursable:	10	_	10		_	10	10	_	
Total	16		16	18		18	18		18
Total.	10	-	10	10	-	10	10	-	10
Office of Administration									
Direct:	33	-	33	35	-	35	35	-	35
Reimbursable:	-	-	-	-	-	-	-	-	-
Total:	33	-	33	35	-	35	35	-	35
Office of the Director									
Direct:	2	-	2	2	-	2	2	-	2
Reimbursable:	-	_	-	-	-	-	-	-	-
Total	2	_	2	2	_	2	2	_	2
Total	2		2	2		2	2		2
Total	128	1	129	139	1	140	139	1	140
Includes FTEs whose payroll obligations are supported by the	he NIH Comr	non Fund.							
FTEs supported by funds from Cooperative Research and	0	0	0	0	0	0	0	0	0
Development Agreements.	0	0	0	0	0	0	0	0	0
FISCAL YEAR	Average GS Grade								
2017	12.1								
2018	12.4								
2019	12.4								
2020	12.4								
2021	12.4								

Detail of Full-Time Equivalent Employment (FTE)

GRADE	FY 2019 Final	FY 2020 Enacted	FY 2021 President's Budget
Total, ES Positions	1	1	1
Total, ES Salary	192,254	192,300	192,300
GM/GS-15	22	23	23
GM/GS-14	22	25	25
GM/GS-13	19	23	23
GS-12	17	18	18
GS-11	4	5	5
GS-10	0	0	0
GS-9	8	8	8
GS-8	5	5	5
GS-7	0	0	0
GS-6	0	0	0
GS-5	0	0	0
GS-4	2	2	2
GS-3	1	1	1
GS-2	1	1	1
GS-1	0	0	0
Subtotal	101	111	111
Grades established by Act of July 1, 1944 (42 U.S.C. 207)			
Assistant Surgeon General	0	0	0
Director Grade	0	0	0
Senior Grade	1	1	1
Full Grade	0	0	0
Senior Assistant Grade	0	0	0
Assistant Grade	0	0	0
Subtotal	1	1	1
Ungraded	45	45	45
Total permanent positions	99	110	110
Total positions, end of year	148	158	158
Total full-time equivalent (FTE) employment, end of year	129	140	140
Average ES salary	192,254	192,300	192,300
Average GM/GS grade	12.4	12.4	12.4
Average GM/GS salary	118,249	121,918	122,869

Detail of Positions¹

¹ Includes FTEs whose payroll obligations are supported by the NIH Common Fund.